S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal

Immunovant (IMVT) Stock Price, News & Analysis

$32.52
+1.09 (+3.47%)
(As of 03/27/2024 ET)
Today's Range
$31.28
$33.13
50-Day Range
$30.27
$40.54
52-Week Range
$14.05
$45.58
Volume
932,768 shs
Average Volume
1.31 million shs
Market Capitalization
$4.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.88

Immunovant MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
47.2% Upside
$47.88 Price Target
Short Interest
Bearish
15.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.74mentions of Immunovant in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$659,896 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.70) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.54 out of 5 stars

Medical Sector

479th out of 939 stocks

Biological Products, Except Diagnostic Industry

74th out of 157 stocks

IMVT stock logo

About Immunovant Stock (NASDAQ:IMVT)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

IMVT Stock Price History

IMVT Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Immunovant Awarded U.S. Patent for IMVT-1402
IMVT Jul 2024 30.000 call
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
IMVT Mar 2024 40.000 call
IMVT Mar 2024 32.000 call
IMVT Apr 2024 45.000 put
IMVT Jan 2025 12.500 put
IMVT Mar 2024 29.000 put
IMVT Mar 2024 37.500 put
IMVT Mar 2024 37.000 call
IMVT Mar 2024 32.000 put
IMVT Mar 2024 33.000 put
IMVT Mar 2024 36.000 call
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares
See More Headlines
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/27/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.88
High Stock Price Target
$57.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+47.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
16 Analysts

Profitability

Net Income
$-210,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.78 per share

Miscellaneous

Free Float
138,319,000
Market Cap
$4.72 billion
Optionable
Optionable
Beta
0.67
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

IMVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings
or view top-rated stocks.

What is Immunovant's stock price target for 2024?

16 Wall Street analysts have issued 1-year price objectives for Immunovant's shares. Their IMVT share price targets range from $32.00 to $57.00. On average, they anticipate the company's share price to reach $47.88 in the next year. This suggests a possible upside of 47.2% from the stock's current price.
View analysts price targets for IMVT
or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2024?

Immunovant's stock was trading at $42.13 at the start of the year. Since then, IMVT shares have decreased by 22.8% and is now trading at $32.52.
View the best growth stocks for 2024 here
.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest in March. As of March 15th, there was short interest totaling 9,350,000 shares, an increase of 7.7% from the February 29th total of 8,680,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 7.1 days. Currently, 15.3% of the shares of the company are short sold.
View Immunovant's Short Interest
.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our IMVT earnings forecast
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

Who are Immunovant's major shareholders?

Immunovant's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.03%), Vanguard Group Inc. (4.01%), Point72 Asset Management L.P. (1.84%), Perceptive Advisors LLC (1.60%), Price T Rowe Associates Inc. MD (1.11%) and Price T Rowe Associates Inc. MD (1.10%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends
.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMVT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners